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Reply to: ‘‘Noradrenaline in the treatment of patients
with hepatorenal syndrome – Back to the roots?’’
and more than 60% of our patients were alcoholic in
etiology.
(5) Relative adrenal dysfunction is a common problem in
patients with cirrhosis with or without sepsis [8,9] and
adrenal insufﬁciency is associated with high urinary
sodium [10]. As pointed out by Dr. Lenz, in some of our
patients ongoing infection cannot be excluded which
might have contributed to the adrenal insufﬁciency and
high urinary sodium, however, all our patients were cov-
ered with broad spectrum antibiotics.
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Letters to the EditorTo the Editor:
We thank Dr. Lenz for his interest in our paper. We agree with his
view on noradrenaline and terlipressin therapy in hepatorenal
syndrome (HRS). It would have been ideal to compare the two
vasopressors if given as infusion and dose monitored by mean
arterial pressure. However, terlipressin has been used as bolus
therapy in most of the studies [1]. Gerbes et al. [2] treated 32 con-
secutive patients with HRS with continuous terlipressin infusion
and reported reversal of HRS in 42% of patients in a retrospective
study. They concluded that continuous terlipressin infusion may
achieve response rates comparable with those of bolus adminis-
tration, but possibly at a lower daily dose (3 mg) and with less
severe complications (9%). In our study also, dose, adverse effects,
and response rates with bolus administration were comparable.
However, more studies focusing speciﬁcally on this aspect are
needed to answer this question.
High urinary sodium was unusual in our patients. However,
the following factors may explain this ﬁnding:
(1) In patients with the hepatorenal syndrome, there is renal
sodium retention, and urinary sodium is characteristically
less than 10 mmoles per liter throughout their clinical
course [3]. However, occasional patients with the hepato-
renal syndrome have been recognized in whom urinary
sodium is consistently greater than 10 mmoles per liter
[3]. In some of these patients, urinary sodium is initially
low but increases to levels of approximately 40 mmoles
per liter as renal impairment progresses, and it has been
suggested that this late increase in urinary sodium concen-
tration may represent the possible transition to acute
tubular necrosis [3]. Trawale et al. [4], also demonstrated
acute tubular necrosis in cirrhotic patients with HRS (high
serum creatinine levels, proteinuria <0.5 g/day and no
haematuria).
(2) The current diagnostic criteria for HRS include presence of
cirrhosis, ascites, serum creatinine >1.5 mg/dl after at least
48 h of diuretic withdrawal and volume expansion with
albumin plus absence of shock, treatment with nephro-
toxic drugs, and parenchymal renal disease [5]. The use
of minor criteria (urine sodium <10 mEq/L) and exclusion
of patients with infections is abandoned. The majority of
the trials published showed low urinary sodium and used
the previously established criteria [6], and might have
excluded patients with urine sodium >10 mEq/L.
(3) All our patients were admitted in emergency, hence were
consuming salt without any restriction in their diet and
some of the patients were on diuretics which were with-
drawn only after admission.
(4) A relatively high urinary sodium concentration has been
observed in patients with HRS and alcoholic hepatitis [7]
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